David A. Spellman - Sep 30, 2021 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, CFO and Treasurer
Signature
/s/ Nicole R. Hadas, attorney-in-fact for David A. Spellman
Stock symbol
AKBA
Transactions as of
Sep 30, 2021
Transactions value $
$0
Form type
4
Date filed
10/1/2021, 04:06 PM
Next filing
Mar 2, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Employee Stock Option (Right to Buy) Award $0 +200K $0.00 200K Sep 30, 2021 Common Stock 200K $2.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.